Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
6 pending office actions • 1 client • 6 examiners • 3 art units • 0 of 6 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
GLOBAL PATENT GROUP - MDA has managed 201 career applications within the Biotechnology & Pharmaceuticals technology area. The firm demonstrates a resolved allowance rate pct of 80.0 for these matters. This 80.0 resolved allowance rate pct is achieved with an avg office actions per allowance of 2.5, which provides a metric for the intensity of the prosecution process. Practitioners can use this figure to estimate the resources required for each application.
There are currently 5 pending office actions requiring attention from the firm. These 5 pending office actions represent the firm's engagement with the patent office relative to its 201 career applications. The 2.5 avg office actions per allowance provides a benchmark for practitioners to anticipate the number of responses typically required to reach an allowance in this biotechnology sector. This data shows the firm's results in maintaining its resolved allowance rate pct through consistent interaction with examiners.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (17%) |
| §103 only | 2 (33%) |
| §112 only | 1 (17%) |
| Double-patenting only | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JACKSON, SHAWQUIA | 1 | 78.0% | -3.3% |
| WARD, PAUL V | 1 | 83.2% | -12.2% |
| ROBINSON, MIKHAIL O'DONNEL | 1 | 59.2% | +42.1% |
| AEDER, SEAN E | 1 | 57.0% | +19.9% |
| JOHNSON, CHRISTOPHER LINDSAY | 1 | 46.9% | +81.0% |
| XU, XIAOYUN | 1 | 60.0% | +31.8% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18799303 | PTPN11 INHIBITORS | WARD, PAUL V | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18145602 | METHODS FOR THE DETECTION AND TREATMENT OF PROSTATE CANCER | XU, XIAOYUN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18145595 | UREA INHIBITORS OF MICRO-RNA | JOHNSON, CHRISTOPHER LINDSAY | 53d overdue |
| 18787216 | INHIBITORS OF MUTANT IDH1 AND IDH2 | ROBINSON, MIKHAIL O'DONNEL | — |
| 18193917 | METHODS FOR THE DETECTION AND TREATMENT OF LUNG CANCER | AEDER, SEAN E | — |
| 18145602 | METHODS FOR THE DETECTION AND TREATMENT OF PROSTATE CANCER | XU, XIAOYUN | — |
| Client (Assignee) | Pending OAs |
|---|---|
| University of Texas | 6 |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| 1691 | 1 |
| 1797 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18938730 | IMIDAZOPIPERAZINE INHIBITORS OF TRANSCRIPTION ACTIVATING PROTEINS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | JACKSON, SHAWQUIA | DP | Non-Final OA | — | Pending | Nov 06, 2024 | |
| 18799303 | PTPN11 INHIBITORS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | WARD, PAUL V | DP | Non-Final OA | — | Pending | Aug 09, 2024 | |
| 18787216 | INHIBITORS OF MUTANT IDH1 AND IDH2 | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | ROBINSON, MIKHAIL O'DONNEL | §112 | Non-Final OA | — | Pending | Jul 29, 2024 | |
| 18193917 | METHODS FOR THE DETECTION AND TREATMENT OF LUNG CANCER | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | AEDER, SEAN E | 1642 | §103Other | Non-Final OA | — | Pending | Mar 31, 2023 |
| 18145595 | UREA INHIBITORS OF MICRO-RNA | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | JOHNSON, CHRISTOPHER LINDSAY | 1691 | §103 | Non-Final OA | 53d overdue | Pending | Dec 22, 2022 |
| 18145602 | METHODS FOR THE DETECTION AND TREATMENT OF PROSTATE CANCER | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | XU, XIAOYUN | 1797 | §101 | Non-Final OA | — | Pending | Dec 22, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial